{"ticker": {"uuid": "cd0e7663-fc52-4c33-899c-f7e33a7a0105", "symbol": "BLRX", "name": "BioLineRx Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "BioLineRx, Hemispherian to present GLIX1 ovarian cancer data at ESMO", "summary": "BioLineRx and Hemispherian are set to present preclinical data on GLIX1 at the 2026 European Society for Medical Oncology Annual Congress. This data demonstrates strong synergy between GLIX1, a TET2 activator, and PARP inhibitors in homologous recombination-proficient ovarian can", "url": "https://www.biospectrumasia.com/news/98/28071/biolinerx-hemispherian-to-present-glix1-ovarian-cancer-data-at-esmo.html", "source_name": "BioSpectrum Asia", "published_at": "2026-07-21T08:40:04", "published_display": "21 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/biolinerx-hemispherian-present-data-demonstrating-110000384.html", "source_name": "PR Newswire", "published_at": "2026-07-20T11:00:00+00:00", "published_display": "20 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Preclinical Ovarian Cancer Data Show GLIX1-PARP Synergy", "summary": "BioLineRx and Hemispherian announced that preclinical data demonstrating a strong synergy between GLIX1, a TET2-activating small molecule, and PARP inhibitors in HR-proficient ovarian cancer will be presented as an e-Poster at ESMO 2026. This is significant because HR-proficient ", "url": "https://www.stocktitan.net/news/BLRX/bio-line-rx-and-hemispherian-as-to-present-data-demonstrating-strong-jdnbpl0gsdp4.html", "source_name": "Stock Titan", "published_at": "2026-07-20T11:10:04", "published_display": "20 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Q4 2024 earnings summary", "summary": "BioLineRx (BLRX) reported a significant strategic shift in Q4 2024, focusing on lean drug development in oncology and rare diseases by shutting down U.S. commercial operations and reducing annual cash burn by over 70%. The company entered an exclusive licensing agreement for moti", "url": "https://quartr.com/events/biolinerx-blrx-q4-2024_FeyHcmlc", "source_name": "Quartr", "published_at": "2026-07-17T15:13:36", "published_display": "17 Jul 2026 15:13", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioLineRx (BLRX) Q4 2025 earnings summary", "summary": "BioLineRx (BLRX) reported its Q4 2025 earnings, highlighting a decrease in revenue to $1.2 million, down from $28.9 million in 2024, primarily due to APHEXDA royalties. The company successfully advanced GLIX1 into clinical development for glioblastoma, resolved a legal dispute, a", "url": "https://quartr.com/events/biolinerx-blrx-q4-2025_FeyH812z", "source_name": "Quartr", "published_at": "2026-07-16T19:40:32", "published_display": "16 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to revenue forward of BioLineRX Ltd. \u2013 TASE:BLRX", "summary": "This article presents the enterprise value to revenue forward for BioLineRX Ltd. (TASE:BLRX). It shows the period, value, and change for this financial metric. The content highlights the stock's listing on the Tel Aviv Stock Exchange and provides a general overview of financials.", "url": "https://www.tradingview.com/symbols/TASE-BLRX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T15:13:36", "published_display": "11 Jul 2026 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of BioLineRX Ltd. \u2013 TASE:BLRX", "summary": "This article presents the \"Price to book forward\" financial metric for BioLineRX Ltd. (TASE:BLRX). It shows the value of this metric over different periods and notes that the data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.", "url": "https://www.tradingview.com/symbols/TASE-BLRX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T10:39:44", "published_display": "10 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of BioLineRX Ltd. \u2013 TASE:BLRX", "summary": "This article provides the enterprise value to EBITDA forward for BioLineRX Ltd. (TASE:BLRX) as presented on TradingView. The content is primarily a data point within a financial platform, focusing on a specific financial metric for the pharmaceutical company.", "url": "https://www.tradingview.com/symbols/TASE-BLRX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T07:11:19", "published_display": "10 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx, Hemispherian post synergy in ovarian cancer model", "summary": "BioLineRx and Hemispherian announced strong preclinical data showing therapeutic synergy between their oncology candidate GLIX1 and the PARP inhibitor olaparib in an ovarian cancer model. The low-dose combination achieved tumor reduction comparable to standard chemotherapy withou", "url": "https://grafa.com/en/news/united-states/biolinerx-hemispherian-glix1-ovarian-cancer-data", "source_name": "grafa.com", "published_at": "2026-07-08T15:39:20", "published_display": "08 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (NASDAQ: BLRX) reports GLIX1-PARP synergy in ovarian cancer model", "summary": "BioLineRx and Hemispherian announced new preclinical data demonstrating strong synergistic effects between GLIX1 and the PARP inhibitor olaparib in a patient-derived ovarian cancer xenograft model. This combination showed significantly better efficacy than current treatments and ", "url": "https://www.stocktitan.net/sec-filings/BLRX/6-k-bio-line-rx-ltd-current-report-foreign-issuer-879a985f8943.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:40:26", "published_display": "08 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/biolinerx-hemispherian-announce-preclinical-data-110000407.html", "source_name": "PR Newswire", "published_at": "2026-07-08T11:00:00+00:00", "published_display": "08 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx reports preclinical data on GLIX1 with PARP inhibitor By Investing.com", "summary": "BioLineRx and Hemispherian AS announced positive preclinical data for GLIX1 combined with the PARP inhibitor olaparib in an ovarian cancer model, showing better efficacy than monotherapy even at lower doses. This combination achieved tumor reduction similar to cisplatin in homolo", "url": "https://ng.investing.com/news/stock-market-news/biolinerx-reports-preclinical-data-on-glix1-with-parp-inhibitor-93CH-2590722", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T11:39:20", "published_display": "08 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx\u2019s ovarian cancer data shows GLIX1 can boost PARP drugs", "summary": "BioLineRx and Hemispherian announced new preclinical data showing a strong synergistic effect between GLIX1 and the PARP inhibitor olaparib in a patient-derived ovarian cancer model. The low-dose combination achieved similar tumor reduction to cisplatin, a chemotherapy benchmark,", "url": "https://www.stocktitan.net/news/BLRX/bio-line-rx-and-hemispherian-announce-new-preclinical-data-5sric0hq5d0l.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:11:05", "published_display": "08 Jul 2026 11:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Advances 1.94% as It Approaches Key Resistance at $3.32 - Standard Deviation", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOQ0xSNEt6dGc1aWZma0FrVWxpWFRTZjNOdGFJQWltcFlMZW9RdDFteWdCMjVtT3JkYU5tam5wQ2FBaU5HVlpNNEdGUVhNcTBfQS1iSmxzRkdPVl8wbVdsODFVX2g0RzBsN1FDclEwR0RXRGlLR2hjenJncTNJVkZrVGFaV2V6aWphRTcwcmxYWFNId3hhNmFKR0NuWk5pblo5eHVjR2xESnJIMEx6VDZn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BLRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a brief forecast for BioLineRx Ltd. (BLRX) for 2027, including an average price target of $17.50 based on analysis from two unnamed analysts. It also mentions that no maximum or minimum estimates were provided by these analysts. The forecast includes section", "url": "https://www.tradingview.com/symbols/BOATS-BLRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T02:10:27", "published_display": "27 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRX Ltd. Actuals & Estimates (TASE:BLRX)", "summary": "This article provides financial actuals and estimates for BioLineRX Ltd. (TASE: BLRX), including its current stock price, historical performance, analyst forecasts, and upcoming earnings report. It advises against considering the information as investment advice and encourages re", "url": "https://www.tradingview.com/symbols/TASE-BLRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:10:27", "published_display": "26 Jun 2026 13:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Earnings Call: Pipeline Momentum, Profit Squeeze", "summary": "BioLineRx's Q1 earnings call revealed significant scientific advancement in its glioblastoma pipeline with the GLIX1 trial commencement and increasing royalty income from APHEXDA. However, these positives were overshadowed by a swing to a net loss, a sharp decline in nonoperating", "url": "https://www.theglobeandmail.com/investing/markets/stocks/BLRX/pressreleases/2390110/biolinerx-earnings-call-pipeline-momentum-profit-squeeze/", "source_name": "The Globe and Mail", "published_at": "2026-06-12T16:11:44", "published_display": "12 Jun 2026 16:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Preview: BioLine Rx to Report Financial Results on May 27", "summary": "BioLine Rx (BLRX.US) is scheduled to release its financial results on May 27 ET. Analysts estimate the company to post revenue of USD 343.00K and an EPS of USD-1.04 for Q1 2026. Companies typically hold a conference call around the publication date to discuss financial results an", "url": "https://www.moomoo.com/news/post/70415609/earnings-preview-bioline-rx-to-report-financial-results-on-may", "source_name": "Moomoo", "published_at": "2026-06-06T23:10:18", "published_display": "06 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx shares advance after first patient enrolled in GLIX1 cancer study (BLRX)", "summary": "BioLineRx (BLRX) shares increased after the company announced the enrollment of the first patient in its randomized, controlled Phase 1/2 clinical study for GLIX1. The study is evaluating GLIX1 in adult patients with relapsed/refractory acute myeloid leukemia (AML), a particularl", "url": "https://www.msn.com/en-us/health/other/biolinerx-shares-advance-after-first-patient-enrolled-in-glix1-cancer-study-blrx/ar-AA24bD8D?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-02T14:09:20", "published_display": "02 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JonesTrading Maintains BioLine Rx(BLRX.US) With Buy Rating, Maintains Target Price $12", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOQWIyYzQ2ak9OMUNsRXhlanhJX2tvNWpSd1dZQ1hIUThVRzY4em9fNU96dHQtUG9TZ3FXQmczdVFZRXhVSGlIV0VtTXctZDY1YVhvWENKdG9hdVBEemlWNmwzNHlLLWdWZTVoWERCeldRS1A5RTVvbWhnXzgtZWJpYzNLektRTHVCMi10SUlMNXNDb0hhcWcyamk3aEg4SlVGMWFvcGNkVFBuME1Qcmd4aGtJc0JUUQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Q1 2026 Earnings Transcript", "summary": "BioLineRx (BLRX) recently announced its Q1 2026 earnings, reporting a GAAP EPS of $0.00, significantly surpassing market expectations by $1.04, and revenue of $0.48 million, an 84.6% year-over-year increase. The company also initiated a Phase 1/2a clinical trial for GLIX1 in glio", "url": "https://intellectia.ai/news/stock/biolinerx-blrx-q1-2026-earnings-transcript", "source_name": "Intellectia AI", "published_at": "2026-06-01T11:39:14", "published_display": "01 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BLRX: First Quarter 2026 Results", "summary": "BioLineRx Ltd. (BLRX) reported first-quarter 2026 results, showing license revenues of $477,000 and a net loss of $2.6 million. The company's joint venture, Tetragon Biosciences, has begun a Phase I/IIa study for GLIX1 in glioblastoma and other cancers, with the first patient alr", "url": "https://scr.zacks.com/news/news-details/2026/BLRX-First-Quarter-2026-Results-article/default.aspx", "source_name": "Zacks Small Cap Research", "published_at": "2026-05-29T07:10:03", "published_display": "29 May 2026 07:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Surges 6.5%: Breaking Out or Approaching Resistance? - Jelly Roll Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNX3lsMVVzVTFhM1lHOGNucG14R0NWQmtzdDlpaHJUMnJiZWt5SkhzX3NJRUxYZ2h1WUZVSkU3c3I5SXZ0ZWJYVWFiOXNiXzlHcVo0RnFqbWF3QXRXRjRDMXN3LTNUZzVjMUlXLURpc3YtbHQtZEpqNFd2eTE1UDZOczlYX1A2Vjh3RmxrMEVaRUJoNVJxV2l0dFFFeElvcER0NlhzYXFtOXhyUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOLXNlS1VDOWJJbjJtalFHYnN6VGJXcTBZNWNXT1RjZTFkMnRXbnFYRDVoTHJFaG5RQ09UR0Q1enlZVWRtTVo3U1czeE5ydE41NTFoXzdCOS1XNTI3dWxmU3Y5Vnp4a1pLNnMwYmpYWk45ZXZMczFWRU9ZOUdnbm9XTkwwWFFLeXcyb0ZPempaNmR0RkEzeXRaWFJYd3VmbF9ja1BoMW5yOUYtRDExMmxrTkNmOUJCZ0ZPWmRuSEFtMnVZa0JVeHdROGhMOUJMT0QyWDV0cWhxZw?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Surges Over 9%: Biotech Stock Breaks Above Key Support Level - Sector ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPZFcyUmhFNjlCc2xGczFIb0hLRnFmRFo1cTdneG93SW1jaUpfWGIycTgxeG5XSUY4c0lfUFkzNTFJdXJHWFFTbzVxU0hPZV9pSXQxRDJ5WXc4Y3FNS0VqRWZzcTNqak1sT2M0YzNnaHE3VDJodTM4bnlETU5kSTgtQnMxbE1aSHg1SlhUS2U5Tk5EY004VjMyQzhmdmpMOC1UczFJT1owVXU5RVVwcHhnTW90czJWdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/biolinerx-hemispherian-highlight-data-glix1-110000922.html", "source_name": "PR Newswire", "published_at": "2026-05-22T11:00:00+00:00", "published_display": "22 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx to Report First Quarter 2026 Results on May 27, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/biolinerx-report-first-quarter-2026-110000189.html", "source_name": "PR Newswire", "published_at": "2026-05-20T11:00:00+00:00", "published_display": "20 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx lines up May 27 results call with CEO at 8:30 a.m.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNOC1SQ2VtWDlYWjNCcTczYi1wd1B3RGxYZU5FcVMxYmlYNFY0cFpaTjJZd01FWjFNc0dGdDNyamNLYTNBYllNSElVN1AzQWFnSEhuaEhlWF84OUcxZll2VF9VYmN4TG0yeUt4QjRZU3JISVN6ZlJTMXVPZWZWeUZ2cl9Pd3I1R1ExQlR5QldLekhaZDBpc2dhNW9mdC1ONEl2Q2R5RTdlN1pzQWl5OVFON3N5SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/biolinerx-hemispherian-announce-glix1-data-110000405.html", "source_name": "PR Newswire", "published_at": "2026-05-19T11:00:00+00:00", "published_display": "19 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/biolinerx-hemispherian-announce-first-patient-110000647.html", "source_name": "PR Newswire", "published_at": "2026-04-28T11:00:00+00:00", "published_display": "28 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioLineRx Reports 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxORWVIQ2pPN0lvQTVFQjBmWWVESTI1VElhdXY4MkllRld2SXcxQ2oydnZ1dV9Rd2lobFJTWF9UZlBsWnA5Z2g5SXVXM3hRbzRTMDlVTS1tbGlRQ3JJVVRxYU5pemZrR1k0VEk5MTB2Y1JlWERDeGxQSHRVSjV0aEx1dC1EQnlhN3V1d1VnSHUydGllS3FLOVF1SHF4TWYzVmV0b1lXVTNvdjVrUUNoaDl3SjRhSlZSMFF5RFAtVi1TZFFlZ0wt?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPTVVLS0xLRFpXcDlRUlloLWFBV2J4Z0Q0SllfbjQtbXB1YkVXZFVGSDVLZUp6OG9jQ3o1NW1IdFVBQ0Y5dmFYV2ZMUVowSHExLU8xbl8taG5BaG9fV09oYkZYRkVDQTVHODFXN3BoNV9jNWliX2hTcFlsV0swMnRKRHBXTllfSXE0VFM5bGtoU3l0QlBZSVB3V05RVkRTN0lHLWlfUkZQaFl0bmVGSUVQUmZaVVhaR1BEbTJBRDlkUzN5WVJEV1hpcmNkcml1S1NRaWJNUV92SQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biolinerx (BLRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9IelhXR3VfVGRvYjdnRDZTOFFtMzJKZEwwRUo2aFo2aW9Za0RHZnhzX1luaS1qd01SNjZFYVUzMkdRNHJ4WDFlbk5VOXhtZW5Zd3Rz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:26:01+00:00", "published_display": "25 Apr 2025 00:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for BioLineRx (BLRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9lOHdlM0tGNkJiWFVvRlAxdGY3aHZ0cUxRMFFWQUlVczNUOHYxTzgzNHQzdmotMHMtUDBLVWxTMFAtc0dTaFJOTmtnYWhUcHlHT2J3Mk5DSHJod05ZbFQ4MDI3bWtCMkxjS1JuRW9YcV9OTU1zX2d0Wg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-08-16T11:27:33+00:00", "published_display": "16 Aug 2022 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biolinerx Stock Price Forecast. Should You Buy BLRX?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE5ucFpqMjN4OEloQW90dEtac0I3eEZMVGNZdTBRUzRtOWxQWm16dGpSMDJWaV9DZDJxbFFMZUY3N2wyM0tqaWRENw?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-01T17:10:19+00:00", "published_display": "01 Dec 2020 17:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BioLineRx, Hemispherian to present GLIX1 ovarian cancer data at ESMO", "summary": "BioLineRx and Hemispherian are set to present preclinical data on GLIX1 at the 2026 European Society for Medical Oncology Annual Congress. This data demonstrates strong synergy between GLIX1, a TET2 activator, and PARP inhibitors in homologous recombination-proficient ovarian can", "url": "https://www.biospectrumasia.com/news/98/28071/biolinerx-hemispherian-to-present-glix1-ovarian-cancer-data-at-esmo.html", "source_name": "BioSpectrum Asia", "published_at": "2026-07-21T08:40:04", "published_display": "21 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/biolinerx-hemispherian-present-data-demonstrating-110000384.html", "source_name": "PR Newswire", "published_at": "2026-07-20T11:00:00+00:00", "published_display": "20 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Preclinical Ovarian Cancer Data Show GLIX1-PARP Synergy", "summary": "BioLineRx and Hemispherian announced that preclinical data demonstrating a strong synergy between GLIX1, a TET2-activating small molecule, and PARP inhibitors in HR-proficient ovarian cancer will be presented as an e-Poster at ESMO 2026. This is significant because HR-proficient ", "url": "https://www.stocktitan.net/news/BLRX/bio-line-rx-and-hemispherian-as-to-present-data-demonstrating-strong-jdnbpl0gsdp4.html", "source_name": "Stock Titan", "published_at": "2026-07-20T11:10:04", "published_display": "20 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Q4 2024 earnings summary", "summary": "BioLineRx (BLRX) reported a significant strategic shift in Q4 2024, focusing on lean drug development in oncology and rare diseases by shutting down U.S. commercial operations and reducing annual cash burn by over 70%. The company entered an exclusive licensing agreement for moti", "url": "https://quartr.com/events/biolinerx-blrx-q4-2024_FeyHcmlc", "source_name": "Quartr", "published_at": "2026-07-17T15:13:36", "published_display": "17 Jul 2026 15:13", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Q4 2025 earnings summary", "summary": "BioLineRx (BLRX) reported its Q4 2025 earnings, highlighting a decrease in revenue to $1.2 million, down from $28.9 million in 2024, primarily due to APHEXDA royalties. The company successfully advanced GLIX1 into clinical development for glioblastoma, resolved a legal dispute, a", "url": "https://quartr.com/events/biolinerx-blrx-q4-2025_FeyH812z", "source_name": "Quartr", "published_at": "2026-07-16T19:40:32", "published_display": "16 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of BioLineRX Ltd. \u2013 TASE:BLRX", "summary": "This article presents the enterprise value to revenue forward for BioLineRX Ltd. (TASE:BLRX). It shows the period, value, and change for this financial metric. The content highlights the stock's listing on the Tel Aviv Stock Exchange and provides a general overview of financials.", "url": "https://www.tradingview.com/symbols/TASE-BLRX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T15:13:36", "published_display": "11 Jul 2026 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of BioLineRX Ltd. \u2013 TASE:BLRX", "summary": "This article presents the \"Price to book forward\" financial metric for BioLineRX Ltd. (TASE:BLRX). It shows the value of this metric over different periods and notes that the data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.", "url": "https://www.tradingview.com/symbols/TASE-BLRX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T10:39:44", "published_display": "10 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of BioLineRX Ltd. \u2013 TASE:BLRX", "summary": "This article provides the enterprise value to EBITDA forward for BioLineRX Ltd. (TASE:BLRX) as presented on TradingView. The content is primarily a data point within a financial platform, focusing on a specific financial metric for the pharmaceutical company.", "url": "https://www.tradingview.com/symbols/TASE-BLRX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T07:11:19", "published_display": "10 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx, Hemispherian post synergy in ovarian cancer model", "summary": "BioLineRx and Hemispherian announced strong preclinical data showing therapeutic synergy between their oncology candidate GLIX1 and the PARP inhibitor olaparib in an ovarian cancer model. The low-dose combination achieved tumor reduction comparable to standard chemotherapy withou", "url": "https://grafa.com/en/news/united-states/biolinerx-hemispherian-glix1-ovarian-cancer-data", "source_name": "grafa.com", "published_at": "2026-07-08T15:39:20", "published_display": "08 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (NASDAQ: BLRX) reports GLIX1-PARP synergy in ovarian cancer model", "summary": "BioLineRx and Hemispherian announced new preclinical data demonstrating strong synergistic effects between GLIX1 and the PARP inhibitor olaparib in a patient-derived ovarian cancer xenograft model. This combination showed significantly better efficacy than current treatments and ", "url": "https://www.stocktitan.net/sec-filings/BLRX/6-k-bio-line-rx-ltd-current-report-foreign-issuer-879a985f8943.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:40:26", "published_display": "08 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/biolinerx-hemispherian-announce-preclinical-data-110000407.html", "source_name": "PR Newswire", "published_at": "2026-07-08T11:00:00+00:00", "published_display": "08 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx reports preclinical data on GLIX1 with PARP inhibitor By Investing.com", "summary": "BioLineRx and Hemispherian AS announced positive preclinical data for GLIX1 combined with the PARP inhibitor olaparib in an ovarian cancer model, showing better efficacy than monotherapy even at lower doses. This combination achieved tumor reduction similar to cisplatin in homolo", "url": "https://ng.investing.com/news/stock-market-news/biolinerx-reports-preclinical-data-on-glix1-with-parp-inhibitor-93CH-2590722", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T11:39:20", "published_display": "08 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx\u2019s ovarian cancer data shows GLIX1 can boost PARP drugs", "summary": "BioLineRx and Hemispherian announced new preclinical data showing a strong synergistic effect between GLIX1 and the PARP inhibitor olaparib in a patient-derived ovarian cancer model. The low-dose combination achieved similar tumor reduction to cisplatin, a chemotherapy benchmark,", "url": "https://www.stocktitan.net/news/BLRX/bio-line-rx-and-hemispherian-announce-new-preclinical-data-5sric0hq5d0l.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:11:05", "published_display": "08 Jul 2026 11:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Advances 1.94% as It Approaches Key Resistance at $3.32 - Standard Deviation", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOQ0xSNEt6dGc1aWZma0FrVWxpWFRTZjNOdGFJQWltcFlMZW9RdDFteWdCMjVtT3JkYU5tam5wQ2FBaU5HVlpNNEdGUVhNcTBfQS1iSmxzRkdPVl8wbVdsODFVX2g0RzBsN1FDclEwR0RXRGlLR2hjenJncTNJVkZrVGFaV2V6aWphRTcwcmxYWFNId3hhNmFKR0NuWk5pblo5eHVjR2xESnJIMEx6VDZn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BLRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a brief forecast for BioLineRx Ltd. (BLRX) for 2027, including an average price target of $17.50 based on analysis from two unnamed analysts. It also mentions that no maximum or minimum estimates were provided by these analysts. The forecast includes section", "url": "https://www.tradingview.com/symbols/BOATS-BLRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T02:10:27", "published_display": "27 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRX Ltd. Actuals & Estimates (TASE:BLRX)", "summary": "This article provides financial actuals and estimates for BioLineRX Ltd. (TASE: BLRX), including its current stock price, historical performance, analyst forecasts, and upcoming earnings report. It advises against considering the information as investment advice and encourages re", "url": "https://www.tradingview.com/symbols/TASE-BLRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:10:27", "published_display": "26 Jun 2026 13:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Earnings Call: Pipeline Momentum, Profit Squeeze", "summary": "BioLineRx's Q1 earnings call revealed significant scientific advancement in its glioblastoma pipeline with the GLIX1 trial commencement and increasing royalty income from APHEXDA. However, these positives were overshadowed by a swing to a net loss, a sharp decline in nonoperating", "url": "https://www.theglobeandmail.com/investing/markets/stocks/BLRX/pressreleases/2390110/biolinerx-earnings-call-pipeline-momentum-profit-squeeze/", "source_name": "The Globe and Mail", "published_at": "2026-06-12T16:11:44", "published_display": "12 Jun 2026 16:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Preview: BioLine Rx to Report Financial Results on May 27", "summary": "BioLine Rx (BLRX.US) is scheduled to release its financial results on May 27 ET. Analysts estimate the company to post revenue of USD 343.00K and an EPS of USD-1.04 for Q1 2026. Companies typically hold a conference call around the publication date to discuss financial results an", "url": "https://www.moomoo.com/news/post/70415609/earnings-preview-bioline-rx-to-report-financial-results-on-may", "source_name": "Moomoo", "published_at": "2026-06-06T23:10:18", "published_display": "06 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx shares advance after first patient enrolled in GLIX1 cancer study (BLRX)", "summary": "BioLineRx (BLRX) shares increased after the company announced the enrollment of the first patient in its randomized, controlled Phase 1/2 clinical study for GLIX1. The study is evaluating GLIX1 in adult patients with relapsed/refractory acute myeloid leukemia (AML), a particularl", "url": "https://www.msn.com/en-us/health/other/biolinerx-shares-advance-after-first-patient-enrolled-in-glix1-cancer-study-blrx/ar-AA24bD8D?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-02T14:09:20", "published_display": "02 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JonesTrading Maintains BioLine Rx(BLRX.US) With Buy Rating, Maintains Target Price $12", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOQWIyYzQ2ak9OMUNsRXhlanhJX2tvNWpSd1dZQ1hIUThVRzY4em9fNU96dHQtUG9TZ3FXQmczdVFZRXhVSGlIV0VtTXctZDY1YVhvWENKdG9hdVBEemlWNmwzNHlLLWdWZTVoWERCeldRS1A5RTVvbWhnXzgtZWJpYzNLektRTHVCMi10SUlMNXNDb0hhcWcyamk3aEg4SlVGMWFvcGNkVFBuME1Qcmd4aGtJc0JUUQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Q1 2026 Earnings Transcript", "summary": "BioLineRx (BLRX) recently announced its Q1 2026 earnings, reporting a GAAP EPS of $0.00, significantly surpassing market expectations by $1.04, and revenue of $0.48 million, an 84.6% year-over-year increase. The company also initiated a Phase 1/2a clinical trial for GLIX1 in glio", "url": "https://intellectia.ai/news/stock/biolinerx-blrx-q1-2026-earnings-transcript", "source_name": "Intellectia AI", "published_at": "2026-06-01T11:39:14", "published_display": "01 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BLRX: First Quarter 2026 Results", "summary": "BioLineRx Ltd. (BLRX) reported first-quarter 2026 results, showing license revenues of $477,000 and a net loss of $2.6 million. The company's joint venture, Tetragon Biosciences, has begun a Phase I/IIa study for GLIX1 in glioblastoma and other cancers, with the first patient alr", "url": "https://scr.zacks.com/news/news-details/2026/BLRX-First-Quarter-2026-Results-article/default.aspx", "source_name": "Zacks Small Cap Research", "published_at": "2026-05-29T07:10:03", "published_display": "29 May 2026 07:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Surges 6.5%: Breaking Out or Approaching Resistance? - Jelly Roll Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNX3lsMVVzVTFhM1lHOGNucG14R0NWQmtzdDlpaHJUMnJiZWt5SkhzX3NJRUxYZ2h1WUZVSkU3c3I5SXZ0ZWJYVWFiOXNiXzlHcVo0RnFqbWF3QXRXRjRDMXN3LTNUZzVjMUlXLURpc3YtbHQtZEpqNFd2eTE1UDZOczlYX1A2Vjh3RmxrMEVaRUJoNVJxV2l0dFFFeElvcER0NlhzYXFtOXhyUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOLXNlS1VDOWJJbjJtalFHYnN6VGJXcTBZNWNXT1RjZTFkMnRXbnFYRDVoTHJFaG5RQ09UR0Q1enlZVWRtTVo3U1czeE5ydE41NTFoXzdCOS1XNTI3dWxmU3Y5Vnp4a1pLNnMwYmpYWk45ZXZMczFWRU9ZOUdnbm9XTkwwWFFLeXcyb0ZPempaNmR0RkEzeXRaWFJYd3VmbF9ja1BoMW5yOUYtRDExMmxrTkNmOUJCZ0ZPWmRuSEFtMnVZa0JVeHdROGhMOUJMT0QyWDV0cWhxZw?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Surges Over 9%: Biotech Stock Breaks Above Key Support Level - Sector ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPZFcyUmhFNjlCc2xGczFIb0hLRnFmRFo1cTdneG93SW1jaUpfWGIycTgxeG5XSUY4c0lfUFkzNTFJdXJHWFFTbzVxU0hPZV9pSXQxRDJ5WXc4Y3FNS0VqRWZzcTNqak1sT2M0YzNnaHE3VDJodTM4bnlETU5kSTgtQnMxbE1aSHg1SlhUS2U5Tk5EY004VjMyQzhmdmpMOC1UczFJT1owVXU5RVVwcHhnTW90czJWdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/biolinerx-hemispherian-highlight-data-glix1-110000922.html", "source_name": "PR Newswire", "published_at": "2026-05-22T11:00:00+00:00", "published_display": "22 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx to Report First Quarter 2026 Results on May 27, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/biolinerx-report-first-quarter-2026-110000189.html", "source_name": "PR Newswire", "published_at": "2026-05-20T11:00:00+00:00", "published_display": "20 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx lines up May 27 results call with CEO at 8:30 a.m.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNOC1SQ2VtWDlYWjNCcTczYi1wd1B3RGxYZU5FcVMxYmlYNFY0cFpaTjJZd01FWjFNc0dGdDNyamNLYTNBYllNSElVN1AzQWFnSEhuaEhlWF84OUcxZll2VF9VYmN4TG0yeUt4QjRZU3JISVN6ZlJTMXVPZWZWeUZ2cl9Pd3I1R1ExQlR5QldLekhaZDBpc2dhNW9mdC1ONEl2Q2R5RTdlN1pzQWl5OVFON3N5SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/biolinerx-hemispherian-announce-glix1-data-110000405.html", "source_name": "PR Newswire", "published_at": "2026-05-19T11:00:00+00:00", "published_display": "19 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/biolinerx-hemispherian-announce-first-patient-110000647.html", "source_name": "PR Newswire", "published_at": "2026-04-28T11:00:00+00:00", "published_display": "28 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Reports 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxORWVIQ2pPN0lvQTVFQjBmWWVESTI1VElhdXY4MkllRld2SXcxQ2oydnZ1dV9Rd2lobFJTWF9UZlBsWnA5Z2g5SXVXM3hRbzRTMDlVTS1tbGlRQ3JJVVRxYU5pemZrR1k0VEk5MTB2Y1JlWERDeGxQSHRVSjV0aEx1dC1EQnlhN3V1d1VnSHUydGllS3FLOVF1SHF4TWYzVmV0b1lXVTNvdjVrUUNoaDl3SjRhSlZSMFF5RFAtVi1TZFFlZ0wt?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPTVVLS0xLRFpXcDlRUlloLWFBV2J4Z0Q0SllfbjQtbXB1YkVXZFVGSDVLZUp6OG9jQ3o1NW1IdFVBQ0Y5dmFYV2ZMUVowSHExLU8xbl8taG5BaG9fV09oYkZYRkVDQTVHODFXN3BoNV9jNWliX2hTcFlsV0swMnRKRHBXTllfSXE0VFM5bGtoU3l0QlBZSVB3V05RVkRTN0lHLWlfUkZQaFl0bmVGSUVQUmZaVVhaR1BEbTJBRDlkUzN5WVJEV1hpcmNkcml1S1NRaWJNUV92SQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biolinerx (BLRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9IelhXR3VfVGRvYjdnRDZTOFFtMzJKZEwwRUo2aFo2aW9Za0RHZnhzX1luaS1qd01SNjZFYVUzMkdRNHJ4WDFlbk5VOXhtZW5Zd3Rz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:26:01+00:00", "published_display": "25 Apr 2025 00:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for BioLineRx (BLRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9lOHdlM0tGNkJiWFVvRlAxdGY3aHZ0cUxRMFFWQUlVczNUOHYxTzgzNHQzdmotMHMtUDBLVWxTMFAtc0dTaFJOTmtnYWhUcHlHT2J3Mk5DSHJod05ZbFQ4MDI3bWtCMkxjS1JuRW9YcV9OTU1zX2d0Wg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-08-16T11:27:33+00:00", "published_display": "16 Aug 2022 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biolinerx Stock Price Forecast. Should You Buy BLRX?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE5ucFpqMjN4OEloQW90dEtac0I3eEZMVGNZdTBRUzRtOWxQWm16dGpSMDJWaV9DZDJxbFFMZUY3N2wyM0tqaWRENw?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-01T17:10:19+00:00", "published_display": "01 Dec 2020 17:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 44, "sentiment_summary": {"positive": 17, "negative": 4, "neutral": 23, "score": 57, "total": 44, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 76, "events": [{"event": "earnings", "label": "Earnings", "weight": 10.66, "count": 21}, {"event": "general", "label": "Market update", "weight": 9.9, "count": 18}, {"event": "guidance", "label": "Guidance", "weight": 2.0, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 2.9, "latest_week": "2026-07-17", "one_week_move": -6.1, "four_week_move": -8.2, "twelve_week_move": 27.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.828623, "market_dynamics_buy_signal": false, "relative_strength": -19.242034, "fair_value_gap": -86.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.5351, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.1% over one week, -8.2% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "PR Newswire", "count": 9}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 6}, {"label": "Stock Titan", "count": 5}, {"label": "dars.gov.et", "count": 3}, {"label": "Quartr", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 35}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 21}, {"label": "Market update", "count": 18}, {"label": "Guidance", "count": 3}, {"label": "Balance sheet", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "35", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.1% over one week, -8.2% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "BioLineRx, Hemispherian to present GLIX1 ovarian cancer data at ESMO"}], "updated_at": "2026-07-21T19:40:22.156508+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}